Monopar Therapeutics (NASDAQ:MNPR) Shares Gap Up – Here’s What Happened

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) gapped up prior to trading on Tuesday . The stock had previously closed at $92.75, but opened at $98.00. Monopar Therapeutics shares last traded at $91.22, with a volume of 8,739 shares traded.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MNPR. Leerink Partners started coverage on shares of Monopar Therapeutics in a research note on Monday, November 10th. They issued an “outperform” rating and a $115.00 target price on the stock. Raymond James Financial cut shares of Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and lowered their price objective for the company from $142.00 to $123.00 in a research report on Friday, November 14th. Leerink Partnrs upgraded shares of Monopar Therapeutics to a “strong-buy” rating in a research report on Monday, November 10th. Oppenheimer set a $115.00 target price on Monopar Therapeutics and gave the company an “outperform” rating in a research note on Thursday, October 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $106.20.

Monopar Therapeutics Trading Down 4.9%

The firm has a fifty day moving average of $82.66 and a two-hundred day moving average of $53.36. The company has a market capitalization of $589.38 million, a PE ratio of -25.65 and a beta of 1.35.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). On average, equities analysts expect that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Insider Transactions at Monopar Therapeutics

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 550,229 shares of the business’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total value of $35,000,066.69. Following the transaction, the insider owned 272,026 shares in the company, valued at approximately $17,303,573.86. The trade was a 66.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Monopar Therapeutics

Large investors have recently modified their holdings of the business. Wellington Management Group LLP bought a new position in Monopar Therapeutics during the 3rd quarter valued at approximately $18,904,000. Deerfield Management Company L.P. bought a new position in shares of Monopar Therapeutics during the third quarter valued at approximately $13,048,000. TCG Crossover Management LLC bought a new position in shares of Monopar Therapeutics during the third quarter valued at approximately $12,496,000. Vanguard Group Inc. lifted its stake in Monopar Therapeutics by 140.7% in the third quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock worth $17,005,000 after acquiring an additional 121,729 shares during the period. Finally, Vivo Capital LLC bought a new stake in Monopar Therapeutics in the third quarter valued at $7,391,000. 1.83% of the stock is owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.